(NASDAQ: UTHR) United Therapeutics's forecast annual revenue growth rate of 11.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.58%.
United Therapeutics's revenue in 2026 is $3,128,400,000.On average, 17 Wall Street analysts forecast UTHR's revenue for 2026 to be $148,760,549,545, with the lowest UTHR revenue forecast at $130,590,664,767, and the highest UTHR revenue forecast at $159,653,869,092. On average, 15 Wall Street analysts forecast UTHR's revenue for 2027 to be $164,691,491,175, with the lowest UTHR revenue forecast at $134,681,041,672, and the highest UTHR revenue forecast at $194,142,204,891.
In 2028, UTHR is forecast to generate $187,769,828,239 in revenue, with the lowest revenue forecast at $156,424,624,167 and the highest revenue forecast at $226,391,597,542.